Rifaximin in IBD: Is it time to beat back the bugs as induction therapy in Crohn's disease?

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 457-458

  Prantera, C ^b   Lochs, H ^b   Grimaldi, M ^b   Isaacs, Kim L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE; C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN; PLACEBO; PROTEIN; QUINOLONE DERIVATIVE; RIFAXIMIN;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; CHLAMYDIA TRACHOMATIS; COMPARATIVE STUDY; CROHN DISEASE; DIARRHEA; HEADACHE; HUMAN; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM PARATUBERCULOSIS; NAUSEA; NOTE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT FAILURE; TUBERCULOSIS; YERSINIA ENTEROCOLITICA;

EID: 84876375347     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318280fcf5     Document Type: Note

References (9)

1. Feagins L, Holubar S, Kane S, et al. Current strategies in the management of intra-abdominal abscesses in Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:842-850.
2. Blumberg R. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009;27:455-464.
3. van Loo E, Dijkstra G, Ploeg R, et al. Prevention of postoperative recurrence of Crohn's disease. J Crohns Colitis. 2012;6:637-646.
4. Holubar S, Cima R, Sandborn W, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;16:CD001176.
5. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349-358.
6. Sartor R. Microbial influences in inflammatory bowel disease. Gastroenterology. 2008;134:577-594.
7. Khan K, Ullman T, Ford A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:661-673.
8. Brown R, Xue Q, Jiang Z, et al. Pretreatment of epithelial cells with rifaximin alters baterial attachment and internalization profiles. Antimicrob Agents Chemother. 20010;54:388-396.
9. Sipponen T, Savilahti E, Kolho K, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.